Welcome!

News Feed Item

Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024

LONDON, March 19, 2014 /PRNewswire/ --


Prospects  For  Leading  Players

Vaccine  manufacturing  technology  and  services  -  your  guide  to  trends  and  revenue  prospects  for  vaccine  production

What's the outlook for producing vaccines? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 205 page report provides 104 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2014 to 2024, with growing revenues.

Forecasts  from  2014-2024  and  other  analyses  show  you  commercial  prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read the full transcript of four exclusive expert opinion interviews from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales:
- Dr. Eluemuno Blyden, CEO and Founder, AfriVax
- Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
- Dr. Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
- Dr. Stefan Beyer, Managing Director, Vibalogics

You  will  find  prospects  for  key  submarkets

In addition to analyses of the overall world market, you will see revenue forecasting for these five world-level vaccine submarkets to 2024:
-    Paediatric vaccines
-    Influenza vaccines
-    Adult prophylactic vaccines
-    Therapeutic vaccines
-    Contract vaccine manufacturing

Our investigation shows business research and analysis with individual revenue forecasts and discussions. Which vaccine submarket will generate the most revenues? How will the vaccine contract manufacturing market expand? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.

To see an exec summary of this report please email Sara Peerun on [email protected]

What  are  the  prospects  for  vaccine  contract  manufacturing  in  the  leading  regions  and  countries?

Events and progress worldwide will influence the market, especially outsourced vaccine manufacturing in emerging countries.

In our study you will find individual revenue forecasts to 2024 for 11 vaccine contract manufacturing national markets:
-    US
-    Japan
-    Germany
-    Italy
-    Spain
-    France
-    UK
-    Russia
-    China
-    India
-    Brazil
-    RoW

Many opportunities exist within the vaccines contract manufacturing market. Greater uptake of existing technology and products worldwide will also stimulate the industry and market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what is likely to achieve the most success.

Leading  companies  and  potential  for  market  growth

Overall world revenue for the vaccines contract manufacturing market will reach $705.62m in 2014, our study forecasts. We predict strong revenue growth from 2014 to 2024. Our research shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
-    Baxter BioPharma Solutions
-    Boehringer Ingelheim
-    Catalent
-    Charles River Laboratories
-    IDT Biologika GmbH
-    Lonza
-    Meridian Life Science
-    Sigma-Aldrich
-    SynCo Bio Partners
-    OSO BioPharmaceuticals Manufacturing

In general, a company profile gives you the following information:
-    Overview of the company
-    Discussion of a company's activities and outlook including descriptions of leading products
-    Recent financial results
-    Assessment of recent developments - mergers and acquisitions (M&A),  new products, and collaborations, inc. alliances, partnerships and joint ventures

To see an exec summary of this report please email Sara Peerun on [email protected]

What  issues  will  affect  the  vaccine  contract  manufacturing  market?

Our new report discusses issues and events affecting the vaccine contract manufacturing market. You will find discussions, including qualitative analyses:
-    Healthy pipeline of vaccine products
-    Cell-based techniques - mammalian cell lines, avian-derived cells, plant-based processes and other methods
-    Pandemic preparedness
-    Pricing, regulation and government policy
-    Perception of risk in outsourcing vaccine manufacturing

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How  the Vaccine  Manufacturing  Technology  and  Services:  World  Market  Forecast  2014-2024:  Prospects  For  Leading  Players  report  helps  you

In summary, our 205 page report gives you the following knowledge:
-    Revenues forecasts to 2024 for the overall world vaccine market and 5 submarkets - discover the industry's prospects, finding promising places for investments and revenues
-    Assessment of  10 leading companies, and others, discovering their activities and outlooks
-    Market forecasting to 2024 for 11 leading national vaccine contract manufacturing markets - USA, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India, China and RoW
-    View opinions from our survey, seeing 4 interviews with leading authorities
-    Investigation of competition and opportunities influencing sales
-    Discussion of what stimulates and restrains the vaccine contract manufacturing market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information  found  nowhere  else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how our report could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the vaccines market and vaccine contract manufacturing market. You will find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at            [email protected] or call Tel : +44 (0) 20 7336 6100

Or click on http://www.visiongain.com/Report/1221/Vaccine-Manufacturing-Technology-and-Services-World-Market-Forecast-2014-2024

Companies  Listed  in  this  report:

AAI Pharma Services Corp.
AbbVie
Accugenix
Activaris Biotech
Adamis Pharmaceuticals
Aduro Biotech
Advanced Bioscience Laboratories, Inc.
Advaxis
AFFiRis
Afrivax
Agenus
ALK- Abello
Alpha Biologics
AlphaVax
Althea Technologies, Inc.
Ambiopharm
Amgen
AmProtein
Antigen Express
Antigenics
Aptuit CTS
Argos Therapeutics
Artelis
AstraZeneca
 ATMI
ATMI LifeSciences
AuRx
Avista Capital Partners
Batavia
Bavarian Nordic
Baxter
Baxter BioPharma Solutions
Bayer
Bayer Healthcare
Bayhill Therapeutics
Beijing Tiantan Biological Products
Bellicum Pharmaceuticals
Ben Venue Laboratories
Bend Research
Berna Biotech
Bharat Biotech International
Binnopharm
Biofabri
BioKangtai
Biological E. Serum Institute
Biomay
Biondvax
Bionor Pharma
BioReliance
BioSante Pharmaceuticals
Biovest International
Biovian
BN ImmunoTherapeutics
Boehringer Ingelheim
Bosch
Cadila Pharmceuticals
Cancer Advances
Cardinal Health
Catalent
Catalent (Shanghai) Clinical Trial Supplies
Catalent Pharma Solutions
CatScl
Celldex Therapeutics
Cellexus Limited
CEL-SCI
Celtic Pharma
Cerebricon
CG Therapeutics
Charles River Biopharmaceutical Services
Charles River Laboratories
Chengdu Institute of Biological Products
China National Biotech Corporation
Chiron B.V
Circassia
CMC Biologics
Cobra Biologics
Colby Pharmaceutical
Cook Pharmica
Corden Pharma
Covance
Crucell
CSL Biologicals
Cytos Biotechnology
Cytovance Biologics
Daiichi Sankyo
Dalian Hissen Bio-Pharm
DBV Technologies
Dendreon
DSM Biologics
Dynport Vaccine
EMD Serono
Emergent BioSolutions
Endocyte
Etubics
Eurogentec Biologics
FiberCell
Frazier Healthcare
Fujifilm Diosynth Biotechnologies
Galena
Gcon
GE Healthcare Life Sciences
GE Wave Biotech
GeneCure Biotechnologies
Genetic Immunity
Genocea Biosciences
GenPhar
GenVec
GeoVax
GlaxoSmithKline Biologicals
Gliknik
Globelmmune
Goodwin Biotechnology Inc.
Gradalis
Grand River Aseptic Manufacturing
GSK
Hawaii Biotech
Heat Biologics
Hospira
HTD Biosystems
iBio
IDT Biologika GmbH
immatics biotechnologies
Immune Response Biopharma
Immune Targeting Systems
Immunitor
ImmunoCellular Therapeutics
ImmunoFrontier
Immunomic Therapeutics
Immunotope
Immunovaccine
Immunovative Therapies
ImmunsanT
ImVisioN Therapeutics
Innogenetics Biologicals
Inovio Pharmaceuticals
Intercell Corporation
Inviragen
Invitrogen
Irvine Scientific
Janssen Alzheimer Immunotherapy
Japan Vaccine Co
Jennerex
JHP Pharmaceuticals
JN-International Medical
Johnson & Johnson
Jubilant HollisterStier
Kuhner
Leidos
LG Life Sciences
LigoCyte Pharmaceuticals
Liquidia Technologies
Lonza
MabVax Therapeutics
Medicago
MedImmune
Meisser Filtration
Memgen
Merck
Merck Serono
Meridian Life Science
Millipore
Mitsubishi Tanabe Pharma
MorphoSys
MP Biomedicals
NanoBio
Nanotherapeutics
Nascent Biologics
NewLink Genetics
Northwest Biotherapeutics
Novadigm Therapeutics
Novartis
Novartis Vaccines and Diagnostics
NovaRX
Novasep
Novavax
OncoPep
Oncothyreon
Opal Therapeutics
Opexa Therapeutics
Optimer Biotechnology
Orban Biotech
Organon Teknika Corporation
OSO Biopharmaceuticals Manufacturing
Pall Life Sciences
Pantec
Paragon Bioservices
Patheon
PaxVax
PBS Biotech
Penn Pharma
Pfizer (Wyeth Pharmaceuticals)
Pfrenex
PharmAthene
Philip Morris International
Piedmont Research Center
Pierre-Guérin Biolafitte
Pique Therapeutics
Polynoma
Prima Biomed
ProBioGen
Profectus BioSciences
Protein Sciences Corporation
Rame-Hart Sanovo
Refine Technology
Riemser Pharma GmbH
Roche
SAFC
Sanaria
Sanofi Pasteur
Sanofi Pasteur MSD
Sartorius Stedim Biotech
Selecta Biosciences
Selecta RUS
Shanghai Sunway Biotech
ShangPharma Corporation  
Shantha Biotech
Sigma Aldrich
Soligenix
Stallergenes
Stemline Therapeutics
Sumagen
Sunovion Pharmaceuticals
Synco Bio Partners
Takeda
TapImmune
TD Vaccines
Theraclone Sciences
Thermo Fisher scientific
Thymon
Transgene
TVAX Biomedical
United Biomedical
Vaccine Technologies
Vaccinogen
Vaxart
VaxInnate
VaxOnco
Vibalogics
Vivalis
Waisman Biomanufacturing
Wave Biotech
Xcellerex
Xencor
ZellWerk
Zhangjiang Biotech & Pharmaceutical Base
Zhejiang Jiang Yuan Tang Biotechnology Corporation

Other Organisations Mentioned in This Report

Aaron Diamond AIDS Research Center
Aeras Global TB Vaccine Foundation
Agência Nacional de Vigilância Sanitária (ANVISA)
Centers for Disease Control and Prevention CDC (US)
Chinese State Food and Drug Administration (SFDA)
Defense Advanced Researched Projects Agency (DAPRA)
Emory University
European Medicines Agency (EMA)
Executive European Commission (European Union)
Health Canada
Hospital Clínic de Barcelona
Infectious Disease Research Institute (IDRI)
International AIDS Vaccine Initiative (IAVI)
Ministry of Industry and Trade (Russia)
Murdoch Childrens Research Institute
National Institute of Health (US)
PATH
Research Foundation for Microbial Diseases of Osaka University
The Department of Health and Human Services (HHS) (US)
The Drug Enforcement Administration (DEA) (US)
The Food and Drug Administration (FDA) (Korean)
The Food and Drug Administration (FDA) (US)
The National Institute of Allergy and Infectious Diseases (NIAID)
The U.S. Department of Health and Human Services Office of Biomedical Advanced Research and Development Authority (BARDA)
The United Nation Industrial Development Organisation (UNIDO)
US Naval Medical Research Center
Vaccine Manufacturers Associations (India)
World Health Organisation (WHO)

To see an exec summary of this report please email Sara Peerun on [email protected]


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Leading companies, from the Global Fortune 500 to the smallest companies, are adopting hybrid cloud as the path to business advantage. Hybrid cloud depends on cloud services and on-premises infrastructure working in unison. Successful implementations require new levels of data mobility, enabled by an automated and seamless flow across on-premises and cloud resources. In his general session at 21st Cloud Expo, Greg Tevis, an IBM Storage Software Technical Strategist and Customer Solution Architec...
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, discussed some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he covered some of the best practices for structured team migration an...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...